Advice
Following a full submission
darunavir (Prezista®) is accepted for use within NHS Scotland, co-administered with ritonavir and in combination with other antiretroviral medicinal products, for the treatment of human immunodeficiency virus (HIV-1) infection in highly pre-treated adult patients who have failed on more than one regimen containing a protease inhibitor (PI).
At 24 and 48 weeks, darunavir, in combination with low dose ritonavir, showed a significant improvement in the reduction of viral load compared with other protease inhibitor plus ritonavir regimens.
Download detailed advice90KB (PDF)
Medicine details
- Medicine name:
- darunavir 300mg tablets (Prezista)
- SMC ID:
- 378/07
- Indication:
- Human immunodeficiency virus (HIV-1) infection
- Pharmaceutical company
- Tibotec (Janssen-Cilag Ltd)
- BNF chapter
- Infections
- Submission type
- Full
- Status
- Accepted
- Date advice published
- 11 June 2007